JHVEPhoto/iStock Editorial via Getty Images
- Merc (New York Stock Exchange:Mark) has halted development of two monoclonal antibody candidates that it was eyeing as fixed-dose combinations with its blockbuster product Keytruda (pembrolizumab).
- Vibostolimab is an anti-TIGIT antibody, while favezelimab is an anti-LAG-3 antibody.
- The fixed-dose combination was fepostulimab and Keytruda
https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1420834981/image_1420834981.jpg?io=getty-c-w750
Source link